The Use Of Anthrax And Orthopox Therapeutic Antibodies From Human Origin In Biodefense | 9398
Journal of Marine Science: Research & Development
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
It is impossible to protect whole nations from the effects of bioterrorism by preventive vaccination.
There are too many possible agents, the costs would be exorbitantly high, and the health risks associated with
complex mass vaccination programs would be unacceptable for the public health authorities. Adequate protection,
however, could be provided via a combination of rapid detection and diagnosis with proper treatment for those
exposed to biological weapon agents. Preferably this should be done with therapeutics, which would be beneficial
in all stages of infection to disease. Monoclonal antibodies, preferably from human origin, can be used to prevent
severe complications by neutralizing or blocking the pathological elements of biological agents and these are the
optimal candidates to be deployed in case of biological warfare or a bioterrorist event.
Recent research in aerosol challenged rabbits has shown that the application of a combination of a
human monoclonal antibody against the protective antigen (PA) and one against the lethal factor (LF) of the
anthrax toxin is highly efficacious even when given 48 hours after the exposure.
In this models, all animals are symptomatic around 30 hrs after exposure and all exposed but untreated
rabbits have died around 90 hrs after exposure. The successfully used effective therapeutic antibodies were fully
human IgG1 (κ-light chain) antibodies, with an affinity of around 10-10 M against the protective antigen (PA) and
10-9 M against the lethal factor (LF) toxin components of
The lifesaving treatment of the animals with a normal dose has proven to still be
effective when the treatment is given 48 hours after the lethal dose in a model where the mean time to death of
untreated animals is around 90 hrs after exposure. This is important for the real life setting as not everybody will
immediately be aware of the infection with anthrax spores, or will have access to immediate treatment. The ability
of the dual antibody approach, enabling successful treatment even when victims are clearly symptomatic, will have
a significant impact on managing the anthrax threat.
Stef Stienstra is Strategic and creative development manager in biomedical science, who works internationally for several medical
and biotech companies as scientific advisory board member. He is also an active reserve-officer of the Royal Dutch Navy in his
rank as Commander (OF4) and Lector at the Rhein-Waal University of Applied Sciences at the Faculty of Political Sciences, Peace
& Security studies. For the Dutch Armed Forces he is CBRNe specialist with focus on biological and chemical threats. He is also
manager of the group of medical- and environmental functional specialist within the 1 CMI Command (Civil Military Interaction)
of the Dutch Armed Forces. In his civilian position he is at this moment developing with MT-Derm in Berlin (Germany) a novel
intradermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ?Grand
Challenge? grant. With IQ Therapeutics in Groningen (The Netherlands) he develops therapeutic antibodies against anthrax and
orthopox viruses and with Hemacon in D?sseldorf (Germany) he develops an innovative blood separation unit. For Infection
Control in Eemnes (The Netherlands) he develops a bio-disinfection system for bioterrorism consequence management and
works on freelance basis for several consulting companies. He has finished both his studies in Medicine and in Biochemistry in
The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-haematology, biodefense and
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals